Lifeboat Foundation

It sucks that the primary reason this has not gone forward is because it is off patent.

This video is reproduced from a presentation I gave to the Euro-Geroscience Task Force “Challenges in Developing Geroscience Drug Trials” held March 23, 2022 in Toulouse, France. It gives an introduction to the state of research on rapamycin as a potential longevity and healthspan drug and some of the challenges and opportunities for clinical development.

Year 2022 😗😁

Summary: A rare genetic mutation that causes blindness also appears to be associated with above-average intelligence, a new study reports.

Source: University of Leipzig

Continue reading “How a Gene Mutation Causes Higher Intelligence” »

The 2023 edition of the exclusive Longevity Investors Conference is fast approaching, bringing together investors, companies and researchers in Gstaad, Switzerland in September. One of the speakers at this year’s conference is scientist, writer and presenter Dr Andrew Steele, the author of the best-selling book Ageless: The new science of getting older without getting old. When it comes to his views on longevity, Steele sits firmly in the camp that aging, like cancer, is something that humanity should be focused on curing.

Longevity. Technology: Last year, Steele told us he was “absolutely convinced” curing aging is possible, but that significant questions remain around how quickly we can get there. As he prepares to speak to more than 100 investors at LIC, we caught up with Steele to see how his views on longevity have evolved, and what he would say to those considering investing in the field.

First and foremost, Steele, who recently published a new, free chapter of Ageless on the moral, ethical and social consequences of treating aging, believes that longevity represents a huge “human opportunity” for investors.

Electron tunneling associated with ferritin was proposed as early as 1988, but it is still viewed skeptically despite substantial evidence that it occurs. In our recent paper published in IEEE Transactions on Molecular, Biological and Multi-Scale Communications, my co-authors and I review the evidence of electron tunneling in ferritin, as well as the evidence that such electron tunneling may be used by biological systems that include the retina, the cochlea, macrophages, glial cells, mitochondria and magnetosensory systems.

While these diverse systems fall in different fields of study, we hope that this article will raise awareness of the mechanism of electron tunneling associated with ferritin and encourage further research into that phenomenon in biological systems that incorporate ferritin, particularly where there is no apparent need for the iron storage functions of ferritin in those systems.

Ferritin is an iron storage protein that self-assembles into a 12-nanometer diameter spherical shell that is 2 nanometers thick, and it can store up to ~4,500 iron atoms in an 8-nanometer diameter core. With an evolutionary history that appears to stretch back more than 1.2 billion years, it might seem rather old, but it should be kept in mind that single-celled organisms are believed to have first evolved ~3.5 billion years ago. As such, it may have taken more than 2 billion years for ferritin to evolve. When the first multicellular organisms evolved ~600 million years ago, members of the ferritin family of proteins were likely present, and they can be found today in almost all plants and animals.

Do you ever mesh your other hobbies with the space stuff? Yes. I once turned the results of one of my experiments into a musical. In 2020, during the lockdowns, I put a scientific instrument on my balcony to measure light, sound and pollution before and after the pandemic. I ended up with several graphs and thought, Why not turn these into a musical? So, me and my brother got several musical instruments and played notes according to how high or low each point on the graph was. We actually submitted that to the NASA SpaceApps COVID-19 Challenge and became one of the top six global winners.

Do you think you’ll study space science at university when you’re older? I think so. Either aerospace or astrophysics, or maybe both.

Continue reading “‘I’m really into planetary defence’: Meet the 13-year-old whose science project could protect Earth from asteroids” »

The first gene therapy that can treat Duchenne muscular dystrophy (DMD) has been approved by the U.S. Food and Drug Administration; it will be marketed as Elevidys (delandistrogene moxeparvovec-rokl) by Sarepta Therapeutics Inc. Children aged four to five with the disorder and confirmed gene mutations will be eligible to receive the one-time treatment if insurers approve, as the cost is $3.2 million per patient.

DMD is caused by mutations in a gene called dystrophin, which results in a serious lack of functional dystrophin protein. The gene therapy works by sending a gene that can produce a shortened version of the dystrophin protein to patients; the company has termed it Elevidys micro-dystrophin.

In a new paper published today in Nature, researchers at the Francis Crick Institute have outlined the structure and function of a protein complex that is required to repair damaged DNA and protect against cancer.

Every time a cell replicates, mistakes can happen in the form of mutations, but specialized proteins exist to repair the damaged DNA.

People with mutations in a DNA repair protein called BRCA2 are predisposed to breast, ovarian and prostate cancers, which often develop at a young age. In the clinic, these cancers are treated with a drug that inhibits PARP, another protein needed for DNA repair.

Summary: Scientists used mathematics to explain the social phenomenon of six degrees of separation.

Their work suggests that the balance between the cost and benefit of maintaining social connections shapes the global human social network. According to their findings, individual efforts to optimize their social connections result in an average of six steps between any two people.

Continue reading “Six Degrees of Connection: A Mathematical Take on Social Ties” »

Researchers at the University of California San Diego School of Medicine have led a study to examine a potential new treatment option for patients with non-alcoholic steatohepatitis (NASH)-related fibrosis.

The results, published in the June 24, 2023, online edition of The New England Journal of Medicine, found that a drug that mimics a hormone in the body improved both liver fibrosis, or scarring of the liver, and liver inflammation in patients with NASH.

“Identifying an effective drug for NASH is extremely promising for patients as currently there are no FDA-approved therapies for this condition,” said Rohit Loomba, MD, the study’s first author and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. “NASH can adversely impact the quality of life in patients and can progress to cirrhosis. Its complications can lead to death or liver transplantation. Our findings will further the science of this disease and provide a potential new treatment option to those affected by NASH-related fibrosis.”